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Background: In the randomized HORIZONS-AMI trial, implantation of paclitaxel-eluting stents (PES), as compared with bare-metal stents (BMS), 
significantly reduced recurrent ischemia necessitating repeat revascularization procedures in STEMI pts undergoing PCI, with similar 1-year rates of 
death, reinfarction and stent thrombosis (ST). We assessed the impact of diabetes mellitus (DM) on clinical outcomes in this trial.
Methods: In HORIZONS-AMI, 3,006 pts were randomized in a 3:1 ratio to receive PES or BMS, stratified by the presence of DM. The occurrence 
of ischemia-driven target lesion revascularization (TLR), target vessel revascularization (TVR), major adverse cardiovascular events (MACE: death, 
reinfarction, ischemic TVR or stroke) and ST at 12 months was assessed according to diabetic status.
Results: Of the 3,006 randomized pts, 478 (15.9%) presented with DM. Of those, 364 pts (76%) were randomized to PES, and 114 pts (24%) to 
BMS. The rates of TLR, TVR, reinfarction and ST were comparable between DM vs. non-DM pts, whereas death (6.3% vs. 3.0%, p<0.001), stroke (2.0% 
vs. 0.8%, p=0.02) and non-TVR (9.0% vs. 4.9%, p<0.001) occurred significantly more often in DM pts. Clinical outcomes at 12 months according to 
stent randomization are shown in the Table.
Conclusions: In the large-scale prospective HORIZONS-AMI trial, implantation of PES compared to an otherwise identical BMS in diabetic pts 
resulted in a 55% reduction of TLR, with comparable rates of safety outcomes including stent thrombosis. 
Diabetics Non-Diabetics
PES
n=364
BMS
n=114
P=
PES
n=1892
BMS
n=635
P=
TLR 5.2% 11.2% 0.03 4.6% 7.0% 0.02
TVR 7.2% 12.2% 0.10 5.8% 8.3% 0.03
Death, all-cause 6.1% 7.2% 0.70 3.0% 2.9% 0.88
Cardiac death 5.0% 4.5% 0.82 1.9% 2.4% 0.48
Reinfarction 3.4% 5.6% 0.32 3.7% 4.4% 0.49
Stroke 1.7% 2.8% 0.49 0.9% 0.3% 0.14
MACE 13.5% 18.9% 0.18 15.0% 14.8% 0.41
Stent thrombosis (def/prob) 3.1% 4.5% 0.49 3.4% 3.2% 0.86
